Etoposide Phosphate is a selective and orally active topoisomerase II inhibitor and anticancer chemotherapy drug that inhibits cancer cell growth and induces apoptosis through DNA damage, the p53 pathway, and G2/M phase arrest of the cell cycle.

Method:
A cell viability assay was performed using HCT116 FBXW+/+, FBXW-/-, and p53-/- cell lines. Cells were treated with various concentrations of Etoposide Phosphate (0.025, 0.05, 0.075, 0.1, 0.2, 0.4, 0.6, 0.8, and 1 μM) and incubated for 72 hours to evaluate its effect on cell growth inhibition.

Result:
Etoposide Phosphate inhibited the growth of HCT116 FBXW+/+, FBXW-/-, and p53-/- cells in a concentration-dependent manner. [2]

Method:
Female CD-1 mice were administered a single intravenous dose of Etoposide Phosphate at 50, 100, or 150 mg/kg.

Result:
At all dose levels, light microscopy revealed degeneration of dorsal root ganglion cells, as well as axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and the dorsal funiculi of the spinal cord. [3]